-+ 0.00%
-+ 0.00%
-+ 0.00%
Adaptive Biotechnologies' clonoSEQ features in about 100 abstracts at ASH 2026
Share
Listen to the news
Adaptive Biotechnologies' clonoSEQ features in about 100 abstracts at ASH 2026
  • Adaptive Biotechnologies will present clonoSEQ findings across approximately 100 abstracts, including 27 oral presentations, at ASH Dec. 12-15, 2026, in New Orleans.
  • Across 20 biopharma-sponsored studies, measurable residual disease assessment serves as the primary endpoint in four studies and a secondary endpoint in 11.
  • Multiple myeloma research supports treatment adjustment using clonoSEQ; real-world findings identify patients with sustained disease negativity whose survival matches the general population.
  • Chronic lymphocytic leukemia studies demonstrate clonoSEQ’s use in guiding treatment duration and assessing response.
  • Lymphoma research involving Adaptive shows clonoSEQ can help predict outcomes following initial treatment, complementing imaging.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180300PRIMZONEFULLFEED9880018) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending